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morbidities play a major role in driving antidyslipidemic use in
primary care setting.
PCV80
DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL
FOR EXPLORING THE CLINICAL CONSEQUENCES OF
RIMONABANT IN ADDITION TO DIET AND EXERCISE IN
OVERWEIGHT OR OBESE SUBJECTS
McEwan P1, Nicholls C2, Getsios D3, Caro JJ3
1Cardiff Research Consortium, Cardiff, UK, 2Sanoﬁ-Aventis, Guildford
Surrey, UK, 3Caro Research Institute, Concord, MA, USA
OBJECTIVES: SHAPE is designed to predict long-term clinical
outcomes of management with rimonabant of cardiovascular
risk in overweight or obese subjects. It is a lifetime Markov
model with monthly cycles incorporating at risk, diabetes, car-
diovascular disease and mortality states, and using Framingham
and UKPDS risk equations. The objective of this study was to
derive utility estimates for the model’s health states based on
patients similar to those in rimonabant’s trials. METHODS:
Mean health utility (EQ5D) values were obtained from 36,294
subjects in the Health Outcomes Data Repository Database
(HODaR) of whom 4991 had either an MI, stroke, TIA or
angina event with no previous inpatient history. The HODaR
project collects data from patients who have attended the Cardiff
and Vale NHS Trust in Wales. Utility values associated with spe-
ciﬁc BMI levels were also derived from multivariate analysis on
subjects with a BMI ≥27 kg/m2 adjusting for age, sex and dia-
betes status. RESULTS: Mean age-related health utility was
0.719 for an acute MI event, 0.709 for stroke, 0.698 for TIA,
0.709 for angina and 0.776 for diabetes (with no prior compli-
cations or inpatient history). Mean age adjusted utility decre-
ments associated with these end points were 0.072, 0.185, 0.088,
0.126 and 0.041 for acute MI, stroke, TIA, angina and diabetes
respectively. For BMI, a decrement of 0.014 utilities was esti-
mated and this decrement reﬂects a 1 unit increase in BMI. CON-
CLUSION: This study provides contemporary and relevant
utility values for cardiovascular modeling. The values were
derived from clinical endpoints matching those included in the
model and are well suited to models using Framingham or
UKPDS risk equations.
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VALIDATION OF THE MODE OF ADMINISTRATION OF THE
MEDICATION COMPLIANCE QUESTIONNAIRE
Rosa K1, Fitzgerald KA1, Moller RA2
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OBJECTIVES: The Medication Compliance Questionnaire
(MCQ) measures concepts that may be related to medication
compliance by investigating subjects’ motivation, barriers, atti-
tudes, and beliefs regarding compliance. In the current study, the
MCQ was administered in The Netherlands primarily via postal
survey. However, due to low response rate to postal surveys in
Italy, the MCQ was planned to be administered there primarily
via telephone interviews. The primary goal of the study was to
evaluate the equivalence of the postal mode of the MCQ against
the telephone interview mode, to determine whether the results
could be compared cross culturally. METHODS: Sixty subjects
in Italy who responded to a postal administration of the MCQ
were randomly assigned to one of two groups. Thirty subjects
were administered the MCQ again approximately one week later
by post and the remaining 30 subjects were administered the
questionnaire again approximately one week later by telephone.
RESULTS: As expected, results showed that the telephone mode
of administration resulted in more complete data. Mail admin-
istration resulted in per item missing data rates of 3.3–23.3%
while the phone administration yielded 100% response rates on
all except one question, which was missing only one response.
A difference in the consistency of responses across modes was
found, with more consistency observed in the same mode
between ﬁrst and second administrations compared to alternate
modes. There was also evidence of a response shift in the tele-
phone administration mode including evidence for socially desir-
able response bias. CONCLUSIONS: Based on the results of this
study, it is recommended that the results from the telephone
administration not be considered equivalent to the mail admin-
istration without further examination. It is not advised to make
direct comparisons of MCQ responses between countries
without taking the potential impact of mode of administration
into account.
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VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL
AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATIN-
TREATED PATIENTS WITH PERSISTENTLY LOW HDL-C
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OBJECTIVE: To help health care decision-makers assess the
cost-effectiveness of HDL-c raising therapy, a model was devel-
oped to project lifetime clinical and economic beneﬁts of adding
an HDL-c raising drug in statin-treated patients with persistently
low HDL-c. METHODS: We developed a simulation model
made of two analytic decision sub-models. The ﬁrst sub-model
(Monte-Carlo) created a cohort of patients based on lipid levels
after drug treatment. The second sub-model (Markov) estimated
long-term clinical and cost outcomes (Framingham risk equa-
tions). Validation analyses were performed. RESULTS: Internal
validation: in patients with no history of CVD, the model pre-
dicted a 2 years risk of CHD events of 1.12% and 2.02% risk
for males and females respectively versus 1% and 2% in the
Framingham study. In patients with a history of CVD, the model
predicted 2-year risk of CHD events of 9.15% and 3.20% for
males and females respectively versus 10 and 3.5% respectively
in the published values. External validation: 1) in patients with
low HDL-c, the model predicted a 2.32% risk for CHD events
associated with each 1 mg/dL increment in HDL-c versus 2–3%
in a published meta-analysis 2) by recreating the 4S cohort char-
acteristics and simvastatin treatment effects, the model predicted
cumulative incidences of 14.2% for non-fatal and 5.5% for fatal
CHD events versus 15.9% and 5.0% in the 4S. CONCLU-
SIONS: Based on our validations, this computer simulation
model appears to be a valuable and accurate tool to help evalu-
ate HDL-c raising therapy for patients with persistently low
HDL-c despite statin treatment.
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COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS
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Sicras A1, Navarro R1, F Bobadilla J2, García M3
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pﬁzer Spain,
Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain
OBJECTIVES: Lack of adherence is a major determinant of
inadequate control of cardiovascular risk factors. The aim of this
study is to evaluate the level of therapeutic compliance among
patients with mild to moderate hypertension (HT) and/or dis-
lipidemia (DL), in a primary care setting in daily medical prac-
tice, and to determine factors associated with TC. METHODS:
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A retrospective multicentric study was performed from a one-
year (2005) registry of patients from ﬁve primary care centres in
Spain. Inclusion criteria were as follows: mild to moderate HT
as per JNC-VII, British Hipertensión-Society; and DL as per
NCEP-ATP III. Compliance was estimated by the relationship
between the amount of dispensed and prescribed pills. Demo-
graphic variables, comorbidities, clinical parameters and sanitary
resources were registered. A bivariant analysis and a multiple
lineal regression analysis were done to correct the model.
RESULTS: Compliance was estimated from the total sample of
15,606 patients (HT: 41.7%; DL: 23.1%; HT/DL: 35.2%), in
85.9% (CI = 85.4–86.4%), 81.6% (CI = 81.0–82.2%) and
84.9% (CI = 84.3–85.5%) respectively (p = 0.000; Scheffé).
Explanatory variables of a better compliance in the multivariate
analysis were (beta = 0.832; t = 59.1; p = 0.000): a) direct rela-
tionship: age, labour inactivity, drug price, and b) indirect rela-
tionship: glycemia, triglycerides, LDL and number of active
principles used (p = 0.000). CONCLUSION: Dyslipidemic
patients show a worse compliance than hypertensive patients,
and dyslipidemia worsened global compliance in hypertensive
patients. Certain clinical parameters of control, the age of the
patient and the drug group are related to compliance in daily
medical practice.
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COMPLIANCE IMPROVEMENTS AND HDL CHOLESTEROL
LEVELS IN HYPERTENSIVE PATIENTS IN SPAIN
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OBJECTIVES: Therapeutic compliance (TC) is related to risk
control in the hypertensive patient. Nevertheless there is no much
information on how the improvement of TC impacts on cardio-
vascular risk factors (CVRF), particularly on lipid parameters,
in the Spanish hypertensive patients. To analyze the relationship
among TC improvement (estimated by the relationship between
amount of drug dispensed and amount of drug prescribed), and
the variations in LDL-cholesterol (LDLc) and HDL-cholesterol
(HDL-c) levels. METHODS: Hypertensive patients from ﬁve
Spanish primary care centres, who had registered values of LDLc
and HDLc, between 2004 and 2005, were retrospectively
studied. Changes in TC, LDLc and HDLc were calculated
between mentioned years. Correlation between: a) changes in TC
and HDL, and b) changes in TC and HDL, were calculated using
the Spearman’s Rho test. RESULTS: Of the 6960 hypertensive
patients, 5094 had registered HDL-c levels in 2004 and 2005.
An increase in TC of 3.8% (DE:17.7%) was demonstrated. An
inverse and statistically signiﬁcant relationship between LDLc
and TC (p = 0.003) was demonstrated. No relationship was
found between TC improvement and HDLc (p = 0.9456) CON-
CLUSIONS: In the Spanish hypertensive population, CT
improvements are associated to a decrease in LDLc levels, with
no impact on HDL. Available treatments are not effective enough
to improve HDLc levels in the Spanish hypertensive patient.
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COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS
FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND
HCTZ FOR PATIENTS WITH HYPERTENSION
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OBJECTIVE: Blood pressure control can be difﬁcult to achieve
in hypertension, often requiring combination pharmacotherapy.
A variety of approaches are available, including ﬁxed dose com-
binations (FDC) versus individual components (IC). The purpose
of this analysis was to assess combination valsartan and hydro-
cholorthiazide (HCTZ) therapy in previously antihypertensive
naïve patients. METHODS: A national database of insured
patients ages 18 & older with hypertension were evaluated for
combination valsartan and HCTZ use initiated within 180 days
of each other. Patients had at least two claims for this combina-
tion of pharmacotherapy within one year of their ﬁrst prescrip-
tion. Eligibility included continuous enrollment 110 days prior
to ﬁrst prescription and 365 days following dual therapy. Eligi-
ble patients were antihypertensive naïve 110 days prior to study
drug initiation. Combination pharmacotherapy persistency at
365 days was calculated and sensitivity analysis was performed
for the length of reﬁll gaps. RESULTS: There were 2,022,578
unique patients age18 years or older identiﬁed with hypertension
ICD-9 codes (401.0, 401.1, 401.9, 402.1 & 402.9). After apply-
ing study criteria there were 8711 eligible patients; 8150 FDC
and 561 IC. In assessing ongoing persistence, patients could not
have a reﬁll gap in excess of 120% of previous prescription day’s
supply. FDC persistency was 54% (4362/8150) compared to
19% (109/561) for IC at 365 days (p < 0.0001). Using a more
stringent threshold (80% days supply), FDC was 44%
(3623/8150) vs. IC 16% (91/561) p < 0.0001. Increasing the
threshold (160% days supply) the FDC was 59% (4821/8150)
vs. IC 21% (119/561) p < 0.0001. CONCLUSIONS: Use of FDC
is more common (93.5%) than individual components for this
previously naïve antihypertensive population. The ﬁxed dose
combination therapy group was shown to have signiﬁcantly
better persistence at 365 days vs. the individual components
group, which proved to be quite robust following a sensitivity
analysis.
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CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO
MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN
ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK
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Reduction of cardiovascular risk frequently requires the 
co-administration of multiple antihypertensive (AH) and lipid
lowering (LL) drugs. Fixed combinations of two drugs could
improve daily compliance by simplifying the treatment regimen.
OBJECTIVE: To assess which antihypertensive patients might
beneﬁt from a combination of AH and LL drugs. METHODS:
Hypertensive patients (>=30 years plus >=3 cardiovascular risk
factors or events (CVD), experienced or new users of antihyper-
tensive drugs between June 2003-June 2004)were selected from
the IPCI database in The Netherlands. A written questionnaire
was administered in October 2005 regarding reasons for non-
compliance, likelihood of missing a dose if two pills would be
combined in one, and self-reported medication-taking. Percent-
age of days covered (PDC) with AH medication was calculated
from the prescription records. RESULTS: A total of 729 out of
1473 patients responded, 101 were new users of antihyperten-
sive drugs, 349 had CVD. Respondents (75% male, median age
63 years) used on average 3 drugs, and 40% used LL drugs at
start of follow-up. Side effects, lack of efﬁcacy, and forgetting
